These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15228129)

  • 1. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea.
    Leyden JJ; Thiboutot D; Shalita A
    Cutis; 2004 Jun; 73(6 Suppl):11-7. PubMed ID: 15228129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.
    Breneman D; Savin R; VandePol C; Vamvakias G; Levy S; Leyden J
    Int J Dermatol; 2004 May; 43(5):381-7. PubMed ID: 15117375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae.
    Cook-Bolden FE; Barba A; Halder R; Taylor S
    Cutis; 2004 Jun; 73(6 Suppl):18-24. PubMed ID: 15228130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations.
    Webster G; Rich P; Gold MH; Mraz S; Calvarese B; Chen D
    J Drugs Dermatol; 2009 Aug; 8(8):736-43. PubMed ID: 19663111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks.
    Chang AL; Alora-Palli M; Lima XT; Chang TC; Cheng C; Chung CM; Amir O; Kimball AB
    J Drugs Dermatol; 2012 Mar; 11(3):333-9. PubMed ID: 22395584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
    Eichenfield LF; Alió Sáenz AB
    J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.
    Tschen EH; Katz HI; Jones TM; Monroe EW; Kraus SJ; Connolly MA; Levy SF
    Cutis; 2001 Feb; 67(2):165-9. PubMed ID: 11236229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical treatment of acne rosacea with benzoyl peroxide acetone gel.
    Montes LF; Cordero AA; Kriner J; Loder J; Flanagan AD
    Cutis; 1983 Aug; 32(2):185-90. PubMed ID: 6225627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fixed-combination acne treatment in adolescents.
    Gold LS
    Cutis; 2013 Mar; 91(3):152-9. PubMed ID: 23617089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel.
    Leyden JJ
    J Drugs Dermatol; 2014 Jun; 13(6):685-8. PubMed ID: 24918558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall results of the BEST study following treatment of patients with mild to moderate acne.
    Weiss J; Shavin J; Davis MW
    Cutis; 2003 Feb; 71(2 Suppl):10-7. PubMed ID: 12630670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial.
    Kellett N; West F; Finlay AY
    Br J Dermatol; 2006 Mar; 154(3):524-32. PubMed ID: 16445786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel.
    Cook-Bolden FE
    J Drugs Dermatol; 2012 Apr; 11(4):455-9. PubMed ID: 22453581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BEST study: evaluating efficacy by selected demographic subsets.
    Fernandez-Obregon A; Davis MW
    Cutis; 2003 Feb; 71(2 Suppl):18-26. PubMed ID: 12630671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.
    Langner A; Chu A; Goulden V; Ambroziak M
    Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.
    Pariser DM; Rich P; Cook-Bolden FE; Korotzer A
    J Drugs Dermatol; 2014 Sep; 13(9):1083-9. PubMed ID: 25226009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and selection criteria in the BEST study.
    Rist T; Davis MW
    Cutis; 2003 Feb; 71(2 Suppl):5-9. PubMed ID: 12630669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.
    Lookingbill DP; Chalker DK; Lindholm JS; Katz HI; Kempers SE; Huerter CJ; Swinehart JM; Schelling DJ; Klauda HC
    J Am Acad Dermatol; 1997 Oct; 37(4):590-5. PubMed ID: 9344199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Harper JC
    J Drugs Dermatol; 2015 Apr; 14(4):381-4. PubMed ID: 25844612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.